Year : 2018 | Volume
: 14 | Issue : 12 | Page : 1201--1208
The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma
Esin Oktay1, Utku Oflazoglu2, Yelda Varol3, Ozgur Tanriverdi4, Necla Mermur5, Hayri Ustun Arda6, Lutfiye Demir7, Ozge Keskin1, Tural Ahmadli6, Isil Somali8, Ilhan Oztop9, Nezih Meydan9
1 Department of Medical Oncology, Aydin Government Hospital, Aydin, Turkey
2 Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
3 Department of Chest Diseases, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey
4 Department of Medical Oncology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
5 Department of Medical Oncology, Sivas Numune Government Hospital, Sivas, Turkey
6 Department of Internal Medicine, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey
7 Department of Medical Oncology, Trabzon Medikal Park Hospital, Trabzon, Turkey
8 Department of Medical Oncology, Faculty of Medicine, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
9 Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey
Aims: In this study, we investigated the expression of thyroid transcription factor-1 (TTF-1) in lung adenocarcinoma patients' samples and analyzed the association of TTF-1 with clinicopathological parameters, prognosis, and treatment options in patients with lung adenocarcinoma. Subjects and Methods: This retrospective study enrolled 200 patients who were histologically confirmed lung adenocarcinoma with Stage I-IV disease, between 2008 and 2015 years. The cytological archive of these hospitals' Pathology Department was searched. The available slides and the clinical information were reviewed and correlated. All analyses were conducted by SPSS version 15.0 statistical software.
Results: Sixty-five (32.5%) of the patients showed TTF-1 negativity and 135 (67.5%) of them showed TTF-1 positivity. The median survival for TTF-1 positive and negative patients was 19.6 and 12.2 months, respectively. We did not find any statistical significance in-between the parameters in terms of the survival data. In TTF-1-negative group, the survival time of epidermal growth factor receptor mutation positive (P = 0.049), cytokeratin 7 (CK7) positive (P = 0.009) patients and those who had received curative radiotherapy (P = 0.028) was significantly better as compared to TTF-1-positive group. We also analyzed the relation between TTF-1 and survival outcome or chemotherapy selection in Stage IV disease. We could not identify any correlation between TTF-1 and survival outcome or treatment selection.
Conclusions: This study suggests that TTF-1 is not a favorable prognostic factor in lung adenocarcinoma patients. The prognostic role of CK7 and relationship between TFF-1 expression in lung adenocarcinoma and predictive role of TTF-1 expression for the selection of first-line treatment in Stage IV lung adenocarcinoma should be validated in prospective and randomized studies.
Department of Medical Oncology, Aydin Government Hospital, 35360 Aydin
|How to cite this article:|
Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.J Can Res Ther 2018;14:1201-1208
|How to cite this URL:|
Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Can Res Ther [serial online] 2018 [cited 2020 May 27 ];14:1201-1208
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2018;volume=14;issue=12;spage=1201;epage=1208;aulast=Oktay;type=0